-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on AnaptysBio, Raises Price Target to $76

Benzinga·05/13/2026 14:31:44
Listen to the news
UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $60 to $76.